PMS-AMLODIPINE 5 MG
AMLODIPINE (AMLODIPINE BESYLATE) : 5 MG · DIN 02284065 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is PMS-AMLODIPINE?
PMS-AMLODIPINE 5 MG contains AMLODIPINE (AMLODIPINE BESYLATE) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02284065, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Jul-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-AMLODIPINE used for?
Treatment of mild to moderate essential hypertension and management of chronic stable angina (effort-associated angina).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02284065 |
|---|---|
| Brand name | PMS-AMLODIPINE |
| Generic / active ingredient | AMLODIPINE (AMLODIPINE BESYLATE) : 5 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C08CA01 AMLODIPINE |
| AHFS class | 24:28.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Jul-2009 |
| Original market date | 2009-07-09 00:00:00 |
How is it administered?
Initial 5 mg once daily for hypertension/angina. Max 10 mg/day. Small/fragile/hepatic patients: start 2.5 mg. Pediatrics (6-17 years): 2.5-5 mg once daily.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 header present but content truncated), though typically 15-30°C for this class.
How is it supplied?
2.5 mg: HDPE bottles of 100. 5 mg and 10 mg: HDPE bottles of 100 and 500.
Contraindications
Hypersensitivity to amlodipine or dihydropyridines; breast-feeding; severe hypotension (<90 mmHg systolic); shock/cardiogenic shock; left ventricle outflow obstruction; unstable heart failure.
Warnings and precautions
Increased angina/MI risk upon initiation; hypotension; peripheral edema; caution in congestive heart failure and hepatic impairment. Avoid use with strong CYP3A4 inhibitors.
What can be used instead?
Other Canadian products sharing ATC code C08CA01 AMLODIPINE. 67 of 138 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-AMLODIPINE | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02419572 |
| ACH-AMLODIPINE | 2.5 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02419556 |
| ACH-AMLODIPINE | 5 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02419564 |
| AG-AMLODIPINE | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02369249 |
| AG-AMLODIPINE | 2.5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02369222 |
| AG-AMLODIPINE | 5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02369230 |
| AMLODIPINE | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02331292 |
| AMLODIPINE | 10 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02326817 |
| AMLODIPINE | 10 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02385805 |
| AMLODIPINE | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02429225 |
Who else supplies AMLODIPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMLODIPINE appears in 988 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.